LeMaitre Vascular, Inc. (LMAT)

Market Cap	1.87B
Revenue (ttm)	226.26M
Net Income (ttm)	45.16M
Shares Out	22.59M
EPS (ttm)	1.97
PE Ratio	42.13
Forward PE	36.83
Dividend	$0.80 (0.95%)
Ex-Dividend Date	May 15, 2025

Volume	109,024
Open	83.37
Previous Close	84.39
Day's Range	82.79 - 83.37
52-Week Range	71.42 - 109.58
Beta	0.81
Analysts	Buy
Price Target	100.80 (+21.76%)
Earnings Date	Jul 31, 2025

About LMAT

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheter...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Oct 19, 2006
• Employees: 664
• Stock Exchange: NASDAQ
• Ticker Symbol: LMAT
• Website: https://www.lemaitre.com

Financial Performance

In 2024, LeMaitre Vascular's revenue was $219.86 million, an increase of 13.63% compared to the previous year's $193.48 million. Earnings were $44.04 million, an increase of 46.28%.

Analyst Summary

According to 6 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price target is $100.8, which is an increase of 21.76% from the latest price.

Price Target

$100.8

(21.76% upside)

Analyst Consensus: Buy